Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy

Full text
Author(s):
Campos, Erica C. [1] ; O'Connell, Joao L. [2] ; Malvestio, Lygia M. [1] ; Dias Romano, Minna M. [2] ; Ramos, Simone G. [1] ; Celes, Mara Rubia N. [1] ; Prado, Cibele M. [1] ; Simoes, Marcus V. [3] ; Rossi, Marcos A. [4, 1]
Total Authors: 9
Affiliation:
[1] Univ Sao Paulo, Lab Cellular & Mol Cardiol, Dept Pathol, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP - Brazil
[2] Univ Sao Paulo, Univ Hosp, Div Cardiol, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP - Brazil
[3] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Internal Med Cardiol, BR-14049900 Ribeirao Preto, SP - Brazil
[4] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pharmacol, BR-14049900 Ribeirao Preto, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: European Journal of Pharmacology; v. 670, n. 2-3, p. 541-553, NOV 30 2011.
Web of Science Citations: 20
Abstract

The critical importance of dystrophin to cardiomyocyte contraction and sarcolemmal and myofibers integrity, led us to test the hypothesis that dystrophin reduction/loss could be involved in the pathogenesis of doxorubicin-induced cardiomyopathy, in order to determine a possible specific structural culprit behind heart failure. Rats received total cumulative doses of doxorubicin during 2 weeks: 3.75, 7.5, and 15 mg/kg. Controls rats received saline. Fourteen days after the last injection, hearts were collected for light and electron microscopy, immunofluorescence and western blot. The cardiac function was evaluated 7 and 14 days after drug or saline. Additionally, dantrolene (5 mg/kg), a calcium-blocking agent that binds to cardiac ryanodine receptors, was administered to controls and doxorubicin-treated rats (15 mg/kg). This study offers novel and mechanistic data to clarify molecular events that occur in the myocardium in doxorubicin-induced chronic cardiomyopathy. Doxorubicin led to a marked reduction/loss in dystrophin membrane localization in cardiomyocytes and left ventricular dysfunction, which might constitute, in association with sarcomeric actin/myosin proteins disruption, the structural basis of doxorubicin-induced cardiac depression. Moreover, increased sarcolemmal permeability suggests functional impairment of the dystrophin-glycoprotein complex in cardiac myofibers and/or oxidative damage. Increased expression of calpain, a calcium-dependent protease, was markedly increased in cardiomyocytes of doxorubicin-treated rats. Dantrolene improved survival rate and preserved myocardial dystrophin, calpain levels and cardiac function, which supports the opinion that calpain mediates dystrophin loss and myofibrils degradation in doxorubicin-treated rats. Studies are needed to further elucidate this mechanism, mainly regarding specific calpain inhibitors, which may provide new interventional pathways to prevent doxorubicin-induced cardiomyopathy. (C) 2011 Elsevier B.V. All rights reserved. (AU)

FAPESP's process: 10/13199-1 - Dystrophin and its associated proteins in the pathogenesis of doxorubicin-induced cardiomyopathy
Grantee:Marcos Antonio Rossi
Support Opportunities: Regular Research Grants
FAPESP's process: 09/17787-8 - High blood pressure, cardiac hypertrophy, heart failure and dystrophin-glycoprotein complex
Grantee:Cibele Maria Prado Zinni
Support Opportunities: Research Grants - Young Investigators Grants
FAPESP's process: 10/19216-5 - Hypertension, cardiac hypertrophy and cardiac failure and dystrophin glycoproteins
Grantee:Cibele Maria Prado Zinni
Support Opportunities: Scholarships in Brazil - Young Researchers
FAPESP's process: 09/54010-1 - Sepsis and septic shock: functional and morphological changes in the heart. An experimental study in mice
Grantee:Helio Cesar Salgado
Support Opportunities: Multi-user Equipment Program
FAPESP's process: 09/02942-8 - "In vitro" evaluation of the expression of dystrophin in cardiomyocytes submitted to different stimuli.
Grantee:Lygia Maria Mouri Malvestio
Support Opportunities: Scholarships in Brazil - Master